Gregory Hannah M, Hill Veronica M, Parker Robert W
Anesthesiology and Critical Care, Alabama College of Osteopathic Medicine, Dothan, USA.
Family Medicine, Alabama College of Osteopathic Medicine, Dothan, USA.
Cureus. 2021 Nov 24;13(11):e19870. doi: 10.7759/cureus.19870. eCollection 2021 Nov.
Buprenorphine/Naloxone (Suboxone®) is an efficacious treatment for opioid use disorder (OUD) due to its more convenient dosing, superior safety profile, and decreased incidence of negative side effects when compared to other forms of medications for opioid use disorder (MOUD). In the United States, updated legislation in 2021 entitled, "The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder",released by the Department of Health and Human Services, creates an exemption for the previously required Drug Addiction Treatment Act of 2000 (DATA) waiver for buprenorphine prescribing for clinicians. This legislation was born out of a need for making MOUD more accessible for patients living with OUD as rates of opioid-related deaths in the United States have continued to rise and have increased disproportionately during the time period of the COVID-19 pandemic. This legislation has the potential to improve access to MOUD across all geographic locations, but may have the most profound impact in rural areas where significant disparities and challenges still exist in patients' ability to access buprenorphine. The purpose of this literature review is to 1) examine how MOUD prescribing has changed after previous legislation changes, 2) explore the current state of buprenorphine access for treatment of OUD in rural America, 3) detail existing barriers in patients' ability to access MOUD, and 4) discuss future directions and considerations as a result of new legislation. This literature review found several existing barriers to receiving MOUD such as increasing costs, insufficient education, significant stigma, and the need for more innovative methods of delivery. We also found that there is currently a large opportunity for growth in the number of rural clinicians able to prescribe buprenorphine, particularly in primary care, that may now occur as a result of this new legislation. Overall, this legislation has the potential to have a positive impact on combating OUD, especially in rural areas, and may be a critical step towards ending the current opioid epidemic in the United States as these described barriers are addressed.
丁丙诺啡/纳洛酮(舒倍生®)是治疗阿片类物质使用障碍(OUD)的一种有效疗法,因为与其他形式的阿片类物质使用障碍药物(MOUD)相比,它给药更方便、安全性更高,且负面副作用的发生率更低。在美国,2021年由卫生与公众服务部发布的最新立法《丁丙诺啡治疗阿片类物质使用障碍的实践指南》,为临床医生开具丁丙诺啡处方豁免了此前要求的2000年《药物成瘾治疗法案》(DATA)豁免条款。这项立法源于有必要让患有OUD的患者更容易获得MOUD,因为美国与阿片类药物相关的死亡人数持续上升,且在2019冠状病毒病大流行期间增长幅度不成比例。这项立法有可能改善所有地理位置的MOUD可及性,但可能对农村地区影响最为深远,因为在农村地区,患者获取丁丙诺啡的能力仍然存在巨大差距和挑战。这篇文献综述的目的是:1)研究此前立法变化后MOUD处方开具情况如何改变;2)探讨美国农村地区用于治疗OUD的丁丙诺啡可及性现状;3)详细说明患者获取MOUD能力方面存在的现有障碍;4)讨论新立法带来的未来方向和考虑因素。这篇文献综述发现了接受MOUD存在的几个现有障碍,如成本增加、教育不足、严重的污名化以及需要更创新的给药方式。我们还发现,目前农村地区能够开具丁丙诺啡处方的临床医生数量有很大的增长机会,特别是在初级保健领域,这可能是这项新立法带来的结果。总体而言,这项立法有可能对抗击OUD产生积极影响,尤其是在农村地区,并且随着上述障碍得到解决,可能是朝着结束美国当前阿片类药物流行迈出的关键一步。